The S&P 500 (SNPINDEX: ^GSPC) is made up of 500 companies from 11 different sectors of the economy, but since it's weighted ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and ...
Discover why Vanguard Mid-Cap ETF (VO) is a top buy with its diversification, low expense ratio, and strong momentum.
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...
CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...
10d
Hosted on MSNCRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...
Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results